Dr. David F. Mcdermott, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Js Weill Medical College, Cornell University (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 105
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Js Weill Medical College, Cornell University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 157412
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 105
- Services billed
- 330
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 160 | 61 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Inlyta (axitinib) | 26 |
| Cabometyx (cabozantinib s-malate) | 24 |
| Tafinlar (dabrafenib mesylate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $3,301 in total to this clinician.
| Eisai Inc. | $2,370 |
|---|---|
| Pfizer Inc. | $625 |
| Exelixis Inc. | $306 |
| Consulting Fee | $2,995 |
|---|---|
| Food and Beverage | $306 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Mar 12, 2025 | Consulting Fee Lenvima · Oncology | $2,370 |
| Pfizer Inc. May 1, 2025 | Consulting Fee | $500 |
| Pfizer Inc. Jan 3, 2025 | Consulting Fee | $125 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 2 companies. The companies reported $2,805,793 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma
Merck Sharp & Dohme LLC - A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carcinoma ccRCC
Merck Sharp & Dohme LLC - A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors
Merck Sharp & Dohme LLC - A phase 1, multiple-dose, dose-escalation trial of PT2385 tablets, a HIF-2 inhibitor, in patients with advanced clear cell renal cell carcinoma
Merck Sharp & Dohme LLC - Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
AbbVie Inc. · Recruiting · NCT04777994 - A Phase 2, Randomized, Double-blind, Clinical Study of V940 mRNA-4157 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma INTerpath-004
Merck Sharp & Dohme LLC - M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
AbbVie Inc. - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564
Merck Sharp & Dohme LLC - An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies
Merck Sharp & Dohme LLC - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.